Company Description
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific.
It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass forming machines; and after-sales services, such as spare parts and maintenance services.
It also provides contract development and manufacturing services for customer-owned drug delivery devices.
The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug product, glass packaging, and fill and finish contract manufacturers.
The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
| Country | Italy |
| Founded | 1949 |
| IPO Date | Jul 16, 2021 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 5,521 |
| CEO | Franco Stevanato |
Contact Details
Address: Via Molinella 17 Piombino Dese, PD 35017 Italy | |
| Phone | 39 04 99 31 811 |
| Website | stevanatogroup.com |
Stock Details
| Ticker Symbol | STVN |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $21.00 |
| CIK Code | 0001849853 |
| CUSIP Number | T9224W109 |
| ISIN Number | IT0005452658 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Franco Stevanato | Chief Executive Officer and Executive Chairman |
| Marco Dal Lago | Chief Financial Officer |
| Ugo Gay | Chief Operations Officer |
| Lisa Miles | Chief Communication Officer and Senior Vice President of Investor Relations |
| Paolo De Fabritiis | Chief Human Resources Officer |
| Mauro Stocchi | Chief Business Officer |
| Riccardo Butta | President of Americas |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 14, 2025 | 6-K | Report of foreign issuer |
| Mar 6, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Mar 6, 2025 | 6-K | Report of foreign issuer |
| Mar 6, 2025 | 6-K | Report of foreign issuer |
| Feb 10, 2025 | SCHEDULE 13G/A | Filing |
| Jan 17, 2025 | 6-K | Report of foreign issuer |
| Jan 10, 2025 | SCHEDULE 13G/A | Filing |
| Nov 14, 2024 | SCHEDULE 13G | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | 6-K | Report of foreign issuer |